Xgeva 120 mg PFS
326.24$
271.99$
Xgeva 120 mg PFS is a powerful medication that contains denosumab, a monoclonal antibody designed to address significant health challenges in adults with advanced cancer. This injectable treatment effectively helps prevent severe complications associated with bone metastasis, such as fractures, spinal cord compression, and the need for radiation or surgical interventions. Additionally, Xgeva is utilized for managing giant cell tumors of the bone in patients who are not candidates for surgical removal, particularly in those whose skeletal growth has ceased. It's essential for patients to be aware of potential side effects, including the risk of osteonecrosis of the jaw and low calcium levels, which necessitates regular monitoring. By targeting specific pathways involved in bone resorption, Xgeva aids in maintaining bone integrity and overall quality of life for individuals facing these challenging conditions. Always consult a healthcare professional to determine if Xgeva is the right choice for your treatment plan and to discuss any underlying health concerns. This medication underscores the importance of innovative therapies in oncology, providing hope and improved outcomes for those dealing with complex bone-related issues.
الكمية
Active Pharmaceutical Ingredient
Uses
• Xgeva 120 mg pfs is primarily used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. By inhibiting osteoclast-mediated bone resorption, Xgeva helps maintain bone integrity. This is particularly important for patients who are at risk of fractures, spinal cord compression, or the need for radiation or surgery to the bone. It provides essential support for patients undergoing cancer treatment.
• Xgeva 120 mg pfs is also indicated for the treatment of patients with giant cell tumor of bone that is unresectable or recurrent. This medication targets the underlying bone metabolism that contributes to the growth and proliferation of tumor cells. By managing the condition effectively, Xgeva can help improve the quality of life for these patients. It serves as a vital component in a comprehensive treatment plan.
• In addition, Xgeva 120 mg pfs is utilized for the treatment of hypercalcemia of malignancy that is resistant to hydration and bisphosphonates. This condition can be life-threatening and requires prompt intervention. Xgeva works by decreasing calcium release from bones, helping to restore normal calcium levels in the blood. This effect can significantly alleviate symptoms and complications associated with hypercalcemia.
• Xgeva 120 mg pfs is also approved for the treatment of osteoporosis in patients who are at high risk for fractures. This medication plays a crucial role in strengthening bone density and reducing the likelihood of fractures. For individuals with a history of osteoporosis-related fractures, Xgeva can be an important part of their management strategy. Its use can lead to improved bone health and overall well-being.
Benefits
Xgeva PFS Injection binds to RANKL, a protein that is essential for the formation, function, and survival of osteoclasts (the cells responsible for bone resorption). It inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength of the bone. Along with this treatment, your doctor might ask you to make certain lifestyle changes, such as maintaining good oral hygiene and quitting smoking. Your doctor may ask you to undergo a dental examination before you start the treatment.
Side Effects
Xgeva 120 mg PFS has many adverse effects if it is used in the wrong way. But it varies from person to person, and if you want, you can consult your doctor regarding these adverse effects.
Most Common Side Effects
• Arm or leg pain
• Joint pain
• Muscle or bone pain
• Constipation,
• Abdominal discomfort
• Hair loss
• Skin rash
• Tingling, pain, or numbness that moves down your leg
Common Side Effects
• Upper respiratory tract infection
• Frequent or painful urination, blood in urine, inability to hold urine
• Musculoskeletal
• Severe leg or joint pain
How To Use
Xgeva 120 mg PFS can be administered to you subcutaneously (under the skin) by a doctor or nurse. You should also take calcium and vitamin D supplements while being on treatment with Xgeva 120 mg Prefilled Syringe. Your doctor will determine the correct dose and duration for you, taking into account your age, body weight, and disease condition.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Anti-bone loss injection Xgeva. It may increase the risk of liver damage. It is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Xgeva 120 mg PFS should be used with caution in patients having severe kidney problems. Patients with severe kidney impairment (creatinine clearance < 30 mL/min) or receiving dialysis are at greater risk of developing hypocalcemia. Consult your doctor before receiving Xgeva 120 mg Prefilled Syringe.
• Breastfeeding: Xgeva 120 mg PFS is excreted in milk is unknown. So it is better to consult a healthcare provider if you are a breastfeeding mother before taking this medication.
• Liver: Xgeva 120 mg PFS should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Anti-bone loss injection Xgeva and report any unusual symptoms or changes in liver function to their doctor. The dose of Anti-bone loss injection Xgeva may need to be adjusted in patients with liver disease.
• Pregnancy: Xgeva 120 mg PFS is not recommended for use in pregnant women and women of childbearing potential not using contraception. Women should be advised not to become pregnant during and for at least 5 months after treatment with Denosumab 120 mg Injection. Seek your doctor's advice, as studies on pregnant women and animals have shown significant harmful effects on the developing baby.
• Driving: Xgeva PFS Injection has no or negligible influence on the ability to drive and use machines.

